Physician profile
Benjamin Gross
NPI 1124053665
$3,895.12
in general payments reported to CMS, 2019-2025
32 companies · $2,032 in 2025
The $2,032 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $116 · 2021: $86.56 · 2022: $369 · 2023: $198 · 2024: $1,094 · 2025: $2,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,323.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $578.20 | 2020-2025 | Hizentra |
| Neurocrine Biosciences, INC. | $469.74 | 2023-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $425.52 | 2024-2025 | |
| Ge Healthcare | $230.47 | 2024-2025 | |
| Tonix Medicines, INC. | $228.09 | 2024-2025 | Zembrace Symtouch |
| Catalyst Pharmaceuticals, INC. | $187.53 | 2024-2025 | |
| Brainsway USA INC | $182.29 | 2022-2024 | Brainsway Deep Tms System |
| Vanda Pharmaceuticals INC. | $182.00 | 2025 | Ponvory |
| Argenx US, INC. | $171.57 | 2025 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $168.33 | 2023-2025 | Rexulti, Nuedexta |
| Ucb, INC. | $133.13 | 2024-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $132.30 | 2024 | Valtoco |
| Abbvie INC. | $115.33 | 2021-2024 | |
| Life Molecular Imaging Ltd | $90.58 | 2025 | Neuraceq |
| Livanova USA, INC. | $74.33 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $70.73 | 2022-2025 | Tysabri, Vumerity |
| Eisai INC. | $69.87 | 2025 | |
| Tanabe Pharma America, INC. | $46.66 | 2025 | Radicava |
| Axsome Therapeutics, INC. | $33.57 | 2025 | Auvelity |
| Insightec,INC | $32.03 | 2022 | |
| Glaxosmithkline, LLC. | $30.72 | 2022 | |
| Avanir Pharmaceuticals, INC. | $30.07 | 2020 | |
| Horizon Therapeutics Plc | $26.92 | 2023 | Uplizna |
| Ani Pharmaceuticals, INC. | $26.32 | 2024 | Purified Cortrophin Gel |
| Emd Serono, INC. | $25.66 | 2025 | |
| Alnylam Pharmaceuticals INC. | $23.98 | 2022 | |
| Owp Pharmaceuticals, INC. | $23.89 | 2024 | Subvenite |
| Nestle Healthcare Nutrition INC. | $22.31 | 2023 | |
| Tersera Therapeutics LLC | $20.69 | 2022 | |
| Travere Therapeutics, INC. | $17.94 | 2022 | |
| Vision Quest Industries INC. | $12.26 | 2022 | |
| Mdd US Operations, LLC | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.